SCHEMBL4130762

SCHEMBL4130762

CCN1CCC2(CC1)CCN(c1ccc(C(=O)NC)cc1)CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.49
ITGA2B P08514 1/20 0.49
PARP1 P09874 2/20 0.46
KCNH2 Q12809 1/20 0.46
PARP2 Q9UGN5 1/20 0.46
HDAC3 O15379 3/20 0.45
HDAC8 Q9BY41 3/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HDAC6 Q9UBN7 1/20 0.43
MAPK1 P28482 2/20 0.43
CYP2C19 P33261 2/20 0.43
PLK1 P53350 1/20 0.43
MEN1 O00255 1/20 0.43
CYP3A4 P08684 1/20 0.43
KMT2A Q03164 1/20 0.43
USP2 O75604 2/20 0.43
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147000 0.84 CYP2D6 (0.56) PARP1KCNH2PARP2HDAC3HDAC8
SCHEMBL4140495 0.82 USP2 (0.55) HDAC3HDAC8HDAC6MAPK1CYP2C19
SCHEMBL4142700 0.81 ALDH1A1 (0.44) ITGB3ITGA2BHDAC3HDAC8SMN1; SMN2
SCHEMBL4131567 0.78 HRH3 (0.47) HDAC3HDAC8NPC1RAB9ASMN1; SMN2
SCHEMBL4136937 0.78 HRH3 (0.50) HDAC3HDAC8NPC1RAB9ASMN1; SMN2
SCHEMBL4139979 0.76 HDAC6 (0.42) ITGB3ITGA2BPARP1KCNH2PARP2
SCHEMBL4130983 0.76 HRH3 (0.45) HDAC8NPC1RAB9AHDAC6MAPK1
SCHEMBL26398689 0.76 HDAC6 (0.71) NPC1RAB9ASMN1; SMN2HDAC6MAPK1
SCHEMBL4927822 0.75 HRH3 (0.47) HDAC3HDAC8HDAC6MEN1KMT2A
SCHEMBL4128900 0.75 HRH3 (0.47) HDAC3HDAC8NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 ITGB3 1106/4885ITGA2B 1465/4885PARP1 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.